Drug Profile
Research programme: bryostatin analogues - Synaptogenix/Stanford University
Alternative Names: Bryologs; Bryostatin analogues - Synaptogenix/Stanford UniversityLatest Information Update: 28 Aug 2022
Price :
$50
*
At a glance
- Originator Stanford University
- Developer Synaptogenix
- Class Antidementias; Macrocyclic compounds; Neuroprotectants; Vascular disorder therapies
- Mechanism of Action Protein kinase C stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Alzheimer's disease; Brain injuries; Fragile X syndrome; Niemann-Pick disease type C; Rett syndrome; Stroke
Most Recent Events
- 28 Aug 2022 No recent reports of development identified for preclinical development in Niemann-Pick-disease-type-C in USA
- 28 Aug 2022 No recent reports of development identified for preclinical development in Rett syndrome in USA
- 07 Jul 2021 Synaptogenix receives patent allowance for synaptic growth factor activating compounds in USA